Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Scientists created a ‘woolly mouse’ with mammoth traits. Is it a step toward bringing back the extinct giant?
Scientists working to bring back the woolly mammoth have created genetically engineered mice that they say have several ...
Medindia2d
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...
Yahoo Finance8d
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the US Food & Drug ...
In one dog breed, selection for utility may have selected for obesity
It turned out increased obesity risk in Labradors was linked to the same genes and mechanisms that cause obesity in humans.
Palatin says BMT-801 Phase 2 obesity study met primary endpoint
Technologies announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly ...
Palatin reports ‘positive’ results from Phase 2 study of PL8177
Technologies announced positive topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor agonist, in ...
The Pharma Letter1d
Palatin touts Phase II obesity study results
US drug developer Palatin Technologies (NYSE American: PTN) announced that its BMT-801 Phase II obesity co-administration ...
Morningstar5d
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Orally administered PL8177 is designed to target melanocortin-1 receptors on the surface of cells lining the colon. In a Phase 1 clinical trial, the oral version of PL8177 was shown to effectively ...